Senti Biosciences, Inc.

Senti Biosciences announced the first patient dosed in a pilot trial of SN301A for HCC in China, developed with Celest Therapeutics. SN301A is a CAR-NK therapy targeting GPC3-expressing tumors, utilizing Senti Bio's Gene Circuit technology. The trial aims to evaluate safety and efficacy in advanced GPC3-expressing HCC patients. Senti Bio retains development and commercialization rights outside China, Hong Kong, Macau, and Taiwan.

Senti Biosciences and Celest Therapeutics initiated a pilot trial of SN301A, a CAR-NK cell therapy for hepatocellular carcinoma in China. The trial aims to assess SN301A's safety, pharmacokinetics, and anti-tumor activity in advanced GPC3-expressing HCC patients. Senti Bio retains rights outside China, Hong Kong, Macau, and Taiwan.

ATAI Life Sciences N.V. stock dropped 5.62% to $1.68 with a trading volume of 725,664 shares. The company reported an operating income of $40,000 and a net loss of $26.29 million, resulting in an EPS of -$0.16 and a gross profit of -$43,000. No institutional ratings are available. The biotech sector declined 0.10%, with Senti Biosciences, Inc., Purple Biotech Ltd, and Cingulate Inc showing significant gains.

Senti Biosciences appoints Fran Schulz, a seasoned biotechnology and financial executive, to its Board of Directors. Schulz, with over 30 years of experience, will chair the Audit Committee and contribute to the company's growth and innovation in cell and gene therapies using its Gene Circuit platform.

Senti Biosciences reports positive Phase 1 data for SENTI-202 CAR-NK therapy in R/R AML, with 2/3 patients achieving MRD-negative CR at the lowest dose level, and a well-tolerated safety profile. Dose escalation continues, with additional data expected in 2025.

Senti Biosciences reports positive Phase 1 data for SENTI-202, a CAR-NK therapy for R/R AML, with 2/3 patients achieving MRD-negative CR at the lowest dose level. The therapy is generally well-tolerated, and dose escalation continues with additional data expected in 2025.

Senti Biosciences, Inc. (NASDAQ: SNTI) has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 16,713 shares of Series A Convertible Preferred Stock through a private investment in public equity (PIPE) financing, anticipating gross proceeds of approximately $37.6 million. Investors will have the right to exercise warrants to purchase up to an additional 25,069,500 shares of common stock upon stockholder approval. The PIPE financing is anticipated to close on or before December 5, 2024, subject to customary closing conditions. The Company has also granted an option to purchase an additional 4,444 shares of Preferred Stock and accompanying warrants for gross proceeds of approximately $10.0 million at a subsequent closing to occur no later than December 27, 2024.

NK cell therapy, a promising cancer treatment, sees robust R&D with 140+ companies developing 160+ therapies. Key players include Amgen, Innate Pharma, Nektar Therapeutics, and others. Promising therapies like Bemarituzumab, Monalizumab, and NKTR-225 are in various clinical phases. Recent milestones include Immunitybio's CAR-NK cell therapy for NHL, Nkarta's NKX019 for AAV, and KGen Biotech's SNK01 advancing to Phase II.

Senti Biosciences, Inc. entered a sublease agreement with BKPBIOTECH, Inc. and JLSA2 Therapeutics, Inc. for 7,247 rentable square feet at its headquarters, effective Oct 1, 2024, expiring Apr 30, 2027, with initial monthly rent of $35,147.95, increasing annually.